知镜 Cognispect · 医学文献与研究工作台

Sequential Liraglutide and Setmelanotide Therapy in Bardet-Biedl Syndrome: Metabolic and Renal Outcomes in a Real-World Case Report and Literature Review.

Pasquariello T, Secondulfo F, Roscini AR, Nardi E, Prosperi E, Capasso G, Perna A, Zacchia M.
Nephron · 2026-09-15 · PMID 42743093

文献摘要

Introduction Bardet-Biedl syndrome (BBS) is a syndromic ciliopathy characterized by multiple clinical features, including obesity and kidney disease. Therapeutic options remain limited. Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is approved for obesity in BBS, but real-world data in adults are scarce. This case highlights the synergistic metabolic and nephroprotective effects of a sequential therapeutic strategy combining a glucagon-like peptide-1 receptor agonist and an MC4R agonist. Case presentation We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease. Treatment with liraglutide induced modest weight loss (-3.4%, BMI 35.2→34 kg/m2) and improved urinary albumin-to-creatinine ratio (uACR) and liver enzymes levels within 8 months. Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated. After 12 months of treatment, the patient achieved a 10.5% weight loss compared with baseline (BMI 35.2→31.5 kg/m2), normalization of liver transaminases, reduced liver stiffness, and sustained improvement in uACR, while eGFR remained stable. Fasting insulin and HOMA-IR improved. Metformin, statin, and fenofibrate were discontinued, though fenofibrate was later reintroduced for hypertriglyceridemia. Two interventional studies (n≃10-40, 3-52 weeks) similarly reported consistent reduction in metabolic syndrome burden (METs-Z-BMI-score), liver steatosis, stiffness, and enzymes, while renal biomarkers showed stabilization or improvement, supporting potential hepatoprotective and reno-protective effects. Conclusion Setmelanotide treatment was associated with clinically meaningful weight loss and improvements in liver, kidney, and metabolic parameters in this adult patient with BBS. This case supports the potential role of setmelanotide in the multidisciplinary management of BBS and highlights the need for further studies to better define its effects beyond weight reduction.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。